Cancer diagnosis using nucleic acid hybridization
    4.
    发明授权
    Cancer diagnosis using nucleic acid hybridization 失效
    癌症诊断采用核酸杂交

    公开(公告)号:US5688641A

    公开(公告)日:1997-11-18

    申请号:US322742

    申请日:1994-10-13

    摘要: A method of determining whether a test cell from a given human tissue type is (a) normal, or (b) cancerous or precancerous, by contacting the mRNA of the test cell with a nucleic acid probe which contains a nucleotide sequence at least 15 nucleotides in length which is complementary to a portion of the coding sequence of a candidate tumor suppressor gene, which gene is one that is expressed at a given control level in normal cells of that tissue type; and determining the approximate amount of hybridization of the probe to the mRNA of the test cell, an amount of hybridization one-third or less that seen with the mRNA of a normal cell of that tissue type being an indication that the test cell is cancerous or precancerous. Alternatively, an antibody specific for the candidate tumor suppressor gene product can be substituted for the nucleic acid probe as a means for determining the level of expression of the gene in the test cell. The invention also includes methods of treating a cancerous cell by increasing the level of expression of a candidate tumor suppression gene in the cell; novel candidate tumor suppressor genes; and their use in diagnosis, prognosis, and therapy.

    摘要翻译: 通过使测试细胞的mRNA与含有至少15个核苷酸的核苷酸序列的核酸探针接触来确定来自给定人类组织类型的测试细胞是否是(a)正常或(b)癌性或癌前病变 其长度与候选肿瘤抑制基因的编码序列的一部分互补,该基因是在该组织型正常细胞中以给定对照水平表达的那个; 并且确定探针与测试细胞的mRNA的杂交的大致量,与该组织类型的正常细胞的mRNA相似的三分之一或更少的杂交量是测试细胞是癌性的指示,或 癌前病变 或者,可以将针对候选肿瘤抑制基因产物特异性的抗体替代核酸探针作为测定细胞中基因表达水平的手段。 本发明还包括通过增加细胞中候选肿瘤抑制基因的表达水平来治疗癌细胞的方法; 新型候选肿瘤抑制基因; 并将其用于诊断,预后和治疗。